---
title: Healthcare resource utilization and costs during first salvage therapy for
  relapsed or refractory acute myeloid leukemia in the United States
date: '2023-07-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37486091/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230725180816&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Real-world US healthcare resource utilization (HRU) and costs during
  first salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML)
  are described using IBM MarketScan® data (1/1/2007-6/30/2020). Treatments included
  high- (HIC) and low-intensity chemotherapy (LIC) alone, and gilteritinib, other
  FLT3 tyrosine kinase inhibitors (TKIs), and venetoclax with or without chemotherapy.
  Patients were diagnosed with R/R AML at ≥18 years of age between 1/1/2017-12/31/2019.
  Patient ...
disable_comments: true
---
Real-world US healthcare resource utilization (HRU) and costs during first salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) are described using IBM MarketScan® data (1/1/2007-6/30/2020). Treatments included high- (HIC) and low-intensity chemotherapy (LIC) alone, and gilteritinib, other FLT3 tyrosine kinase inhibitors (TKIs), and venetoclax with or without chemotherapy. Patients were diagnosed with R/R AML at ≥18 years of age between 1/1/2017-12/31/2019. Patient ...